. Author manuscript; available in PMC: 2023 Nov 1.

Published in final edited form as: J Urol. 2022 Jul 5;208(5):1037–1045. doi: 10.1097/JU.0000000000002852

Table 3.

Clinical consequences for decision rules with and without phi.

Rule	Overall			Confirmatory			Subsequent
	Biopsies avoided^# (n, 95% CI)	Reclassifications Missed^# (n, 95% CI)	AUC	Biopsies avoided (n, 95% CI)	Reclassifications Missed (n, 95% CI)	AUC	Biopsies avoided (n, 95% CI)	Reclassifications Missed (n, 95% CI)	AUC
R₁: clinical only	123 (95 – 151)	6 (2 – 11)	0.720	51 (30 – 73)	2 (0 – 5)	0.724	193 (147 – 236)	10 (3 – 18)	0.693
R₂: clinical then PHI	246 (210 – 282)	21 (14 – 28)	^*	187 (149 – 225)	14 (6 – 24)	^*	303 (252 – 356)	26 (15 – 37)	^*
R₃: clinical + PHI (linear)	177 (145 – 209)	14 (8 – 20)	0.727	97 (69 – 125)	8 (2 – 16)	0.745	255 (205 – 301)	18 (10 – 28)	0.681
R₄: clinical or PHI	189 (158 – 222)	15 (9 – 22)	^*	133 (102 – 163)	14 (6 – 24)	^*	245 (195 – 297)	16 (8 – 26)	^*

The number of biopsies avoided, and reclassifications missed from a population of 1000 biopsies with an event rate of 21%, 26% and 15% for the overall, confirmatory, and subsequent biopsies respectively, which are estimated from the cohort of 821 biopsies from the validation set.

Unable to calculate due to multiple thresholds in rule.